AzTrials
AzTrials

PeriodontitisPerioBioTISNCT05511454

Comparison of Salivary and Crevicular Protein Concentrations of FIBA, PLMN, HEMO and ApoH in Healthy and Periodontitis Patients

A study testing Salivary and crevicular samples in people with Periodontitis and Periodontal Diseases, run by University Hospital, Montpellier at 1 site in France.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

Periodontal disease is a multifactorial inflammatory disease of infectious origin. The last epidemiological study concerning periodontitis in France was carried out in 2002-2003 by Bourgeois et al and shows that 95.4% of the patients have a loss of attachment and 82.23% have associated periodontal pockets. Read more about this study

Who is it for?
Ages 18 to 80 yearsHealthy volunteers can take part
Conditions the study is for
Periodontitis, Periodontal Diseases
What is being tested?
Salivary and crevicular samples
Type of treatment
Pill or oral medicine
Could I receive a placebo?
No, everyone receives an active treatment
How many people
118 participants
Where
1 siteFrance
Study dates
22 Jun 2023to 1 Mar 2025
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 80 years
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Who may be able to join

  • Control Group:
  • Patients consulting the Center for Dental Care, Education and Research for the care of their periodontal pathology.
  • Patients with periodontal health according to the 2018 Chicago Classification.
  • Case Group:
  • Patients consulting the Center for Dental Care, Education and Research for the care of their periodontal pathology.
  • Patients with periodontitis according to the Chicago 2018 classification criteria.

Who cannot join

  • General:
  • Pregnancy in progress or planned during the study period, Pregnant or breastfeeding women.
  • Adult protected by law or patient under tutorship or curatorship.
  • Participation in other ongoing biomedical research.
  • Failure to obtain written informed consent after a reflection period.
  • Not be affiliated to a French social security system or a beneficiary of such a system.
Show all 10Show fewer
  • Case Group:
  • Patients with previous periodontal treatment or maintenance.
  • Control Group:
  • There is no prohibition against subjects participating in other research simultaneously.

Trial locations and contacts

1 site in 1 country.

France1 site, 1 recruiting
  • Centre de Soins Dentaires

    Montpellier, 34090

    Margaux VIGNON, MD, m-vignon@chu-montpellier.fr

    Recruiting

Other trials in France

About this study

Periodontal disease is a multifactorial inflammatory disease of infectious origin. The last epidemiological study concerning periodontitis in France was carried out in 2002-2003 by Bourgeois et al and shows that 95.4% of the patients have a loss of attachment and 82.23% have associated periodontal pockets. The presence of bacteria, mostly Gram-negative anaerobes, is not sufficient to explain the heterogeneity of clinical forms. Indeed, there are different risk factors influencing the frequency and severity of periodontitis.

Moreover, the link between systemic pathologies and periodontitis has been widely established: it concerns metabolic syndromes, cardiovascular pathologies, premature pregnancies, autoimmune diseases and Alzheimer disease.

Some research has been done on biomarkers found in periodontitis. Among them, the investigators quote the study which took place within the laboratory of Biochemistry - Clinical Proteomics of Pr Lehmann Sylvain by Mertens et al. It is the only study to date that has established an LC-MRM proteomic profile characteristic of periodontitis: indeed, 4 proteins of plasma origin were highlighted thanks to this technology: hemopexin (HEMO), plasminogen (PLMN), apolipoprotein H and α-fibrinogen (FIBA) were correlated with the presence of periodontitis compared to the control group (p<0.05).

Read the detailed description

Periodontitis can be defined as a multi-factorial infectious disease, initiated by the accumulation of bacterial biofilm on the dental surfaces and causing the destruction of the supporting tissues of the tooth, which can lead to the loss of the dental organ. The high prevalence of these pathologies in the general population makes them an important subject to be considered in public health. This prevalence varies from 56 to 82%. The last epidemiological study in France carried out in 2002-2003 shows that 95.4% of patients have a loss of attachment and 82.23% have associated periodontal pockets. They are related to an imbalance between the microbiota and the host which will be more or less permissive with respect to the quantity and/or the bacterial quality. The presence of bacteria, mostly Gram-negative anaerobes, is not sufficient to explain the heterogeneity of clinical forms. Indeed, undetermined etiological factors create in some patients an environment favorable to the formation of periodontitis, in particular genetic and predisposing factors.

Periodontitis is characterized by variable clinical symptoms and signs that may include visible or non-visible inflammation, spontaneous or provoked gingival bleeding of varying severity, periodontal pocket formation related to attachment and alveolar bone loss, tooth mobility and may lead to tooth loss. In practice, the diagnosis is based on the new Chicago classification but the etiological diagnosis is not so simple with the clinical and radiological tools available today. Bacteriological tests exist to identify certain bacteria responsible for periodontitis, but here again these tests are not sufficiently effective and studies show that there is a significant risk of false positives and negatives.

Some research has been done on biomarkers found in periodontitis. The PubMed database includes a few articles on salivary biomarkers and periodontitis, including a systematic review dating from 2018. Among them, the investigators mention the study that took place in the laboratory of Biochemistry - Clinical Proteomics of Pr Lehmann Sylvain by Mertens et al. It is the only study to date that has established an LC-MRM proteomic profile characteristic of periodontitis: indeed 4 proteins of plasma origin were highlighted thanks to this technology: hemopexin (HEMO), plasminogen (PLMN), apolipoprotein H and α-fibrinogen (FIBA) were correlated to the presence of periodontitis compared to the control group (p<0.05).

  • PLMN: lower level in periodontitis patients than in control patients.
  • HEMO and FIBA: higher levels in samples from patients with aggressive periodontitis.
  • Apolipoprotein H has been identified as a differential diagnosis between aggressive and chronic periodontitis. Its level is significantly higher in patients with aggressive periodontitis.
  • All proteins correlated with periodontal disease are proteins of plasma origin

However, this study is only interested in saliva. However, the proteins found are of plasma origin. The crevicular fluid (present in the sulcus) is a plasma exudate that is easy to collect. More and more studies are interested in this fluid. It would therefore be interesting to analyze it in parallel with saliva.

This assay of proteins in fluids can detect a maximum of 4 to 5 proteins in a multiplex assay, and requires prior knowledge of the proteins being sought. In order to open up the search for new biomarkers, quantification techniques using mass spectrometry coupled with high-performance liquid chromatography provide extensive qualitative and quantitative characterisation of the peptidome and epitranscriptome. Nowadays, with the DIA (Data Independent Acquisition) mode, multiplex detection can be extended to more than 1000 proteins in a single analysis, as shown in a recent study by Sato et al. The advantages of these techniques lie in their high specificity and sensitivity, enabling the detection of thousands of proteins and multiple RNA modifications in micro-samples (microlites).

Being tested
Salivary and crevicular samples
Keywords
Periodontitis, Proteome, ELISA test, Biomarkers
Medical subject headings
Periodontitis, Periodontal Diseases

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Salivary and crevicular samplesOther

    The samples will be taken from patients in both groups who meet the selection criteria during consultations at the Montpellier University Hospital's Odontology Department. During these consultations, a sample will be taken after rinsing the oral cavity with a glass of water. The samples will be taken before the periodontal assessment in order to avoid bleeding.

Study groups in NCT05511454
Study groupRoleWhat they receive
Group of patients with periodontitis (cases)ExperimentalPatients with periodontitis according to the Chicago 2018 classification criteria
Receives: Other: Salivary and crevicular samples
Control groupOtherPatients with periodontal health according to the 2018 Chicago Classification
Receives: Other: Salivary and crevicular samples

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Comparison of plasma protein concentration between the two groups

    Salivary and crevicular concentrations of each of the plasma proteins (FIBA, PLMN, ApoH, HEMO), measured by ELISA in the case and control groups (in µg/mL). Salivary and crevicular samples will be analyzed using specific ultra-sensitive Meso Scale Discovery (MSD) immunoassay kits.

    Measured: 1 day

Secondary outcomes (5)
  1. Comparison of plasma protein concentration according to the stages and grades of periodontitis (in case group).

    Salivary and crevicular concentrations of each of the plasma proteins (FIBA, PLMN, ApoH, HEMO), measured by ELISA in the case group according to the stages and grades of periodontitis stated by the Chicago 2018 classification (in µg/mL). Salivary and crevicular samples will be analyzed using specific ultra-sensitive Meso Scale Discovery (MSD) immunoassay kits.

    Measured: 1 day

  2. Comparison of plasma protein concentration according to the presence or absence of diabetes (in case group).

    Salivary and crevicular concentrations of each of the plasma proteins (FIBA, PLMN, ApoH, HEMO), measured by ELISA in the case group according to the presence or absence of diabetes (in µg/mL). Salivary and crevicular samples will be analyzed using specific ultra-sensitive Meso Scale Discovery (MSD) immunoassay kits.

    Measured: 1 day

  3. Quantitative measure

    Concentrations of each of the plasma proteins (FIBA, PLMN, ApoH, HEMO), measured by ELISA in salivary samples and in crevicular samples (in µg/mL). Salivary and crevicular samples will be analyzed using specific ultra-sensitive Meso Scale Discovery (MSD) immunoassay kits.

    Measured: 1 day

  4. Comparison of salivary and crevicular protein profiles and protein levels after mass spectrometry analysis between subjects with periodontitis and a control group

    Salivary and crevicular concentrations of each of the plasma proteins (FIBA, PLMN, ApoH, HEMO), measured by mass spectrometry analysis for subjects with periodontitis and a control group.

    Measured: 1 day

  5. Comparison of level of free nucleosides found in saliva and crevicular fluid by mass spectrometry between subjects with periodontitis and a control group.

    Comparison of salivary and crevicular epitranscriptomic profiles and free nucleoside levels after mass spectrometry analysis between subjects with periodontitis and a control group.

    Measured: 1 day

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted23 Aug 2022
  2. Study start22 Jun 2023
  3. Primary completion22 Dec 2024 (estimated)
  4. Study completion1 Mar 2025 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Diagnosis
Allocation
Non-randomised
Intervention model
Parallel groups
Model description
Pilot pathophysiological study of comparative ELISA proteomic analysis of salivary and crevicular samples in periodontitis patients vs. control subjects.
Masking
None (open label)
Enrolment
118 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05511454
Sponsor's protocol ID
RECHMPL22_0067
Acronym
PerioBioTIS
Status last verified
Jul 2023
First submitted
19 Aug 2022
Last updated
13 Jul 2023
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

A study testing Salivary and crevicular samples in people with Periodontitis and Periodontal Diseases, run by University Hospital, Montpellier at 1 site in France.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 6 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 13 Jul 2023. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Margaux Dr VIGNON (06.52.82.07.82 ext. +33, m-vignon@chu-montpellier.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Comparison of plasma protein concentration between the two groups (time frame: 1 day). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 Jul 2023.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in